Co-Authors
This is a "connection" page, showing publications co-authored by HESHAM AMIN and GHAZALEH ESKANDARI.
Connection Strength
0.695
-
Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma. J Hematol Oncol. 2023 Jun 13; 16(1):61.
Score: 0.226
-
IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers (Basel). 2020 Jul 02; 12(7).
Score: 0.184
-
Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma. J Hematol Oncol. 2019 07 24; 12(1):80.
Score: 0.173
-
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 03 15; 26(6):1237-1246.
Score: 0.044
-
Validation of a Preclinical Model of Diethylnitrosamine-Induced Hepatic Neoplasia in Yucatan Miniature Pigs. Oncology. 2016; 91(2):90-100.
Score: 0.035
-
Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma. J Hepatocell Carcinoma. 2015; 2:131-42.
Score: 0.033